Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis
Research output: Contribution to journal › Journal article › Research › peer-review
BACKGROUND: Nintedanib plus docetaxel has proven an overall survival benefit over docetaxel monotherapy in second-line treatment of non-small-cell lung cancer of adenocarcinoma histology in the LUME-Lung 1 pivotal trial. No published trials have previously compared nintedanib plus docetaxel with agents – other than docetaxel – that are approved second-line treatments for non-small-cell lung cancer.
METHODS: The relative efficacy of nintedanib plus docetaxel versus second-line agents was evaluated by conducting a network meta-analysis of progression-free survival and overall survival.
RESULTS: Nine suitable studies were identified. The estimated probability of nintedanib plus docetaxel being the best treatment with regard to overall survival was 70% (versus 16% for pemetrexed, 10% for docetaxel and 3% for erlotinib). Results for progression-free survival were similar.
CONCLUSION: In patients with advanced non-small-cell lung cancer of adenocarcinoma histology, results suggest that nintedanib plus docetaxel offers clinical benefit compared with docetaxel alone, when used as second-line treatment, and suggests that this combination may also add clinical benefit compared with erlotinib in this patient group.
| Original language | English |
|---|---|
| Journal | Future Oncology |
| Volume | 11 |
| Issue number | 3 |
| Pages (from-to) | 409-20 |
| Number of pages | 12 |
| ISSN | 1479-6694 |
| DOIs | |
| Publication status | Published - Feb 2015 |
- Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Humans, Indoles, Lung Neoplasms, Mutation, Neoplasm Metastasis, Neoplasm Staging, Receptor, Epidermal Growth Factor, Retreatment, Taxoids, Treatment Outcome
Research areas
ID: 161694609